Literature DB >> 1965208

Chronic progressive external ophthalmoplegia: a correlative study of mitochondrial DNA deletions and their phenotypic expression in muscle biopsies.

Y Goto1, Y Koga, S Horai, I Nonaka.   

Abstract

Deleted mitochondrial DNA (mtDNA) has been shown to coexist with normal mtDNA (heteroplasmy) in muscles from chronic progressive external ophthalmoplegia, including Kearns-Sayre syndrome. In this study, we correlated heteroplasmic mtDNA abnormality with clinical, biochemical and histological findings with the following results: (1) large deletions ranging from 1.8 to 8.8 kb in 22 muscle specimens from 28 patients who had ophthalmoplegia clinically and focal cytochrome c oxidase (CCO) deficiency by histochemistry, (2) no difference in clinical and biochemical findings between patients with and without mtDNA deletions, (3) no relationship between the size, site or populations of deleted mtDNA and respiratory chain enzyme activities in muscles, (4) positive correlation between the number of CCO-deficient fibers and the populations of deleted mtDNA, and (5) higher incidence of CCO-negative fibers in patients with deleted mtDNA than in those with no deletion of mtDNA. These results suggest that deleted mtDNA is, at least in part, responsible for focal CCO deficiency as a phenotypic expression and that the investigation on pathogenetic mechanism of focal CCO deficiency may provide a clue to understanding the underlying pathophysiology in this disorder.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1965208     DOI: 10.1016/0022-510x(90)90014-e

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

1.  A unique junctional palindromic sequence in mitochondrial DNA from a patient with progressive external ophthalmoplegia.

Authors:  T Saiwaki; K Shiga; R Fukuyama; Y Tsutsumi; S Fushiki
Journal:  Mol Pathol       Date:  2000-12

2.  Humanin expression in skeletal muscles of patients with chronic progressive external ophthalmoplegia.

Authors:  Tesseki Kin; Kazuma Sugie; Makito Hirano; Yu-Ichi Goto; Ichizo Nishino; Satoshi Ueno
Journal:  J Hum Genet       Date:  2006-04-26       Impact factor: 3.172

Review 3.  Deletions of the mitochondrial genome.

Authors:  A E Harding; S R Hammans
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

4.  Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction.

Authors:  J Hayashi; S Ohta; A Kikuchi; M Takemitsu; Y Goto; I Nonaka
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

5.  Clinical, morphological, biochemical, and neuroradiological features of mitochondrial encephalomyopathies. Presentation of 19 patients.

Authors:  A Lindner; E Hofmann; M Naumann; G Becker; H Reichmann
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

6.  Mitochondrial encephalomyopathies and cytochrome c oxidase deficiency: muscle culture study.

Authors:  I Nonaka; Y Koga; A Kikuchi; Y Goto
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 7.  [Mitochondrial hearing impairment. Background, genetic predisposition and possibilities for diagnosis].

Authors:  K Riemann; M Pfister; N Blin; S Kupka
Journal:  HNO       Date:  2004-06       Impact factor: 1.284

8.  Visual dysfunction in patients with mitochondrial myopathies. I. Electrophysiologic impairments.

Authors:  G Ambrosio; R De Marco; L Loffredo; A Magli
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

9.  Visual dysfunction in patients with mitochondrial myopathies. II. Contrast sensitivity function.

Authors:  G Ambrosio; U Giani; L Loffredo; R De Marco; P Vastarella
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

10.  A topoisomerase II cleavage site is associated with a novel mitochondrial DNA deletion.

Authors:  R B Blok; D R Thorburn; G N Thompson; H H Dahl
Journal:  Hum Genet       Date:  1995-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.